Back to search results
NCT02427269

University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

Enrolling by Invitation
Not specifiedAges 18+Observational
University of North Carolina, Chapel Hill
~1,000 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Specimen Collection

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Specimen Biorepository
Measured over 10 years
+2 more outcomes measured

Conditions

Barrett's Esophagus
Esophageal Cancer
Intramucosal Adenocarcinoma

Explore related trials

Barrett EsophagusEsophageal AdenocarcinomaEsophageal CarcinomaIntramucosal AdenocarcinomaSquamous Cell Carcinoma

NCT02427269

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UNC Chapel Hill

    Chapel Hill, North Carolinano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nicholas Shaheen, MD, MPH · PRINCIPAL_INVESTIGATOR · UNC Chapel Hill

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female aged 18 and older.
Able to read, comprehend, and complete the informed consent form.
Presenting to UNC hospitals for routine care upper endoscopy for their condition.
Meet one of the following:
Willing to undergo biopsy and blood collection for research purposes.

Exclusion

Unable to read or understand English.
Current incarceration.
Current use of blood thinners such as coumadin, warfarin, clopidogrel, heparin and/or low molecular weight heparin (requires discontinuation of medication 5 days prior to and 6 days after esophagogastroduodenoscopy \[EGD\] and/or ensuring blood thinners have been stopped within an appropriate time frame for that specific agent and in accordance with standard clinical practice).
Known bleeding disorder.

What this trial measures

  • Specimen Biorepository10 years

    To develop a prospective tissue and blood biorepository from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) presenting to UNC hospitals for routine care upper endoscopy for their condition. To create a biorepository for future IRB approved studies that have a tissue and/or blood specimen component.

  • Data10 years

    To collect clinical data from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) that includes demographic data, endoscopic procedure data, and pathology data.

  • Collaboration with other investigators10 years

    integrate Aim 1 and 2 in a manner that will provide an efficient bi-directional flow of clinical information and specimens between laboratory and clinical scientists in order to foster innovative translational research.